VR Logo

Unity Biotechnology Inc. (UBX) download report


Healthcare | Biotechnology & Pharma Research

Unity Biotechnology Inc. (UBX) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging.

IPO Date: 03-May-2018

CEO & Director: Dr. Anirvan Ghosh Ph.D.

Co-Founder & Exec. Director: Dr. Nathaniel E. David A.B., Ph.D.

Listing: NASDAQ: UBX

Country: United States

Headquarters: South San Francisco, CA

Website: https://unitybiotechnology.com

Key Facts

Market cap: $41.43 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-63.88 Mln

Cash: $79.16 Mln

Total Debt: $48.71 Mln

Insider's Holding: 5.09%

Liquidity: Low

52 Week range: $0.57 - 4.97

Shares outstanding: 69,168,896

6 Years Aggregate:

  • CFO: $-307.19 Mln
  • EBITDA: $-304.29 Mln
  • Net Profit: $-327.54 Mln

Stock Performance

Time Period Unity Biotechnology (UBX) S&P BSE Sensex* S&P Small-Cap 600*
YTD-59.15-8.97-18.40
1 month-27.88-3.38-8.42
3 months-48.59-7.93-14.06
1 Year-86.260.55-17.64
3 Years-58.5310.416.75
5 Years--11.456.18
10 Years--12.0510.23
As on 28-Jun-2022 *As on 29-Jun-2022
Year Unity Biotechnology (UBX) S&P Small-Cap 600 S&P BSE Sensex
2021-72.1425.2721.99
2020-27.329.5715.75
2019-55.6620.8614.38